Meta-analysis About Cisplatin Versus Carboplatin in Advanced Non-small Cell Lung Cancer.

Seto Takashi

doi:10.2482/haigan.42.789

Cisplatin based chemotherapy prolog the survival of good performance status patients with advanced non-small cell lung cancer, and improve the quality of life. Recently, Key drug for non-small cell lung cancer is shifting to carboplatin, based on the difference of toxicities. In this study cisplatin based chemotherapy were compared to carboplatin based chemotherapy in meta-analysis about tumor response and 1 year survival rate, in the randomized trials for non-small cell lung cancer. In the analysis on 8 randomized trials comparing cisplatin to carboplatin with same combination drugs, response rate was statistically significantly better in cisplatin base therapy than carboplatin. One year survival rate of Cisplatin and Carboplatin based therapy was 38.9% and 36.8% respectively. In the analysis on 6 randomized studies comparing cisplatin to carboplatin with newer agents combination therapy, response rate and one year survival rate were no significantly differences. One year survival rate of cisplatin and carboplatin based therapy were 37.7% and 36.8% respectively. In the chemotherapy for advanced non-small cell lung cancer, it is reasonable to choose the carboplatin as a key drug for combination therapy with newer agents.

Meta-analysis About Cisplatin Versus Carboplatin in Advanced Non-small Cell Lung Cancer.

Bibliographic Information

Search this article

Description

Journal

References(42)*help

Keywords

Details 詳細情報について

Export

Report a problem